Roivant Statement on Topline Results from EMPOWUR Phase 3 Study in Overactive Bladder
NEW YORK and BASEL, Switzerland, March 19, 2019 /PRNewswire/ -- Today Roivant subsidiary Urovant Sciences, Inc. announced topline results from its Phase 3 EMPOWUR trial of vibegron in patients with overactive bladder. Vibegron achieved statistically significant improvements over placebo on both co-primary endpoints of the study as well as all seven key secondary endpoints. Over 30 million Americans over the age of 40 suffer from overactive bladder.
Roivant also expects numerous readouts for earlier-stage programs including the following:
Roivant also anticipates continued growth at its technology-enabled Health Vants, including Datavant and Alyvant, as well as multiple potential regulatory filings for product approvals in the US and other markets.
Roivant will host its second annual Pipeline Day on Thursday, June 6, 2019 in New York to present information on these and other programs. The event will feature presentations, fireside chats, and Q&A sessions from executives across the Roivant family of companies. Due to limited capacity, attendance is by invitation only. A live webcast will be available to interested parties. Please email email@example.com for further information.
About Roivant Sciences
Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology to drive greater efficiency in R&D and commercialization.
For more information, please visit www.roivant.com.
SOURCE Roivant Sciences